A conjugate [8], called Brentuximab vedotin (SGN-35, Adcetris) is designed, which consists of the anti-CD30 monoclonal antibody SGN-35 has been approved by the US Food and Drug Administration (FDA) in 2011 for the treatment of relapsed or refractory Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL) [9,10]. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.